An evaluation of an optimal sampling strategy for meropenem in febrile neutropenics

Journal of Clinical Pharmacology

Volumn 45, Issue 7, 2005, Pages 832-835

  Ariano, Robert E ^a,b   Zelenitsky, Sheryl A ^a,b   Nyhlén, Anna ^c   Sitar, Daniel S ^b  

^a ST BONIFACE GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

D optimal sampling; Febrile neutropenia; Meropenem; Pharmacokinetics

Indexed keywords

MEROPENEM;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INTERMETHOD COMPARISON; MALE; PLASMA CLEARANCE; POPULATION MODEL; SAMPLING;

ANTI-BACTERIAL AGENTS; CREATININE; FEMALE; FEVER; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; NEUTROPENIA; RESEARCH DESIGN; THIENAMYCINS;

EID: 21044450208     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270005277937     Document Type: Article

References (15)

1. D'Argenio DZ. Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharm. 1981;9:739-756.
2. Westlake WJ. Use of statistical methods in evaluation of in vivo performance of dosage forms. J Pharm Sci. 1973;62:1579-1589.
3. Metzler CM, Elfring GL, McEwen AJ. A User's Manual for NONLIN and Associated Programs. Kalamazoo, Mich: Upjohn; 1974.
4. Jelliffe RW, Schumitzky A, Van Guilder M. User Manual for Version 11.0 USC*PACK Collection of PC Programs. Los Angeles: Laboratory of Applied Pharmacokinetics, University of Southern California; 2002.
5. Ariano R, Duke C, Sitar DS. Population pharmacokinetics of fentanyl in healthy volunteers. J Clin Pharmacol. 2001;41:1-7.
6. Nyhlén A, Ljungberg B, Nilsson-Ehle I. Pharmacokinetics of meropenem in febrile neutropenic patients. Swedish study group. Eur J Clin Microbiol Infect Dis. 1997;16:797-802.
7. Nilsson-Ehle I, Hutchinson M, Haworth SJ, Norrby SR. Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males. Eur J Clin Microbiol Infect Dis. 1991;10:85-88.
8. Ariano RE, Nyhlén A, Donnelly JP, Sitar DS, Harding GKM, Zelenitsky SA. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann Pharmacother. 2005;39:32-38.
9. Bedikian A, Okamoto MP, Nakahiro RK, et al. Pharmacokinetics of meropenem in patients with intra-abdominal infections. Antimicrob Agents Chemother. 1994;38:151-154.
10. D'Angio R, Platt DR, Gannon R. Creatinine clearance: corrected versus uncorrected. Drug Intel Clin Pharm. 1988;22:32-33.
11. Drusano GL, Forrest A, Snyder MJ, Reed MD, Blumer JL. An evaluation of optimal sampling strategy and adaptive study design. Clin Pharmacol Ther. 1988;44:232-238.
12. Forrest A, Ballow CH, Nix DE, Birmingham MC, Schentag JJ. Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrob Agents Chemother. 1993;37:1065-1072.
13. Vinks AT, Mouton JW, Touw DJ, Heijerman HG, Danhof M, Bakker W. Population pharmacokinetics of ceftazidime in cystic fibrosis patients analyzed by using a nonparametric algorithm and optimal sampling strategy. Antimicrob Agents Chemother. 1996;40:1091-1097.
14. Amsden GW, Ballow CH. Prospective validation of an optimal sparse plasma-sampling strategy for estimating ciprofloxacin pharmacokinetics. Pharmacotherapy. 1996;16:937-941.
15. Green B, Duffull SB. Prospective evaluation of a D-optimal designed population pharmacokinetic study. J Pharmacokinet Pharmacodyn. 2003;30:145-161.